BEVERLY, Mass., March 2, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today announced that it has received more data on Kevetrin™, the Company's flagship compound for the treatment of cancers. Analysis of the latest research shows Kevetrin™ is non-genotoxic, contrary to the majority of currently available chemotherapeutic drugs. Genotoxic drugs affect nucleic acids and alter their function. These drugs may directly bind with DNA or may indirectly lead to DNA damage by affecting enzymes involved in DNA replication. A DNA damaging drug results in rapid phosphorylation of H2A.X at Ser 139 by PI3K-like kinases. Kevetrin™ did not induce phosphorylation of H2A.X protein; whereas, other chemotherapy drugs, such as Adriamycin, did induce the phosphorylation of H2A.X as shown by Western blot assay.
Research data announced earlier this week showed that Kevetrin™ reactivates p53, a key protein which plays a critical role in mediating cellular stress responses such as that brought about by DNA-damage. It is therefore vital in regulating a vast array of proteins involved in cell cycle progression, DNA repair, and apoptosis.
Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, "This is another major breakthrough for Kevetrin. p53 activation is considered among the critical molecular events for cancer therapy. The fact that Kevetrin™ reactivated p53 and resulted in tumor suppression in animals with drug resistant cancers was a milestone in oncology on its own, but with Kevetrin™ now proven to be non-genotoxic, we believe this has set the compound at the forefront of developmental cancer therapies." "
Cellceutix is completing formulation production, scheduled for early March 2011, which would produce Kevetrin™ in the dosage form for planned clinical trials. The Company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in May 2011 with human trials to begin thereafter.About Cellceutix
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV